The overall 5-year survival rate of patients with human pancreatic cancer remains less than 8% because of its aggressive growth, early metastasis and resistance to conventional chemoradiotherapy. It is essential to develop innovative and effective therapeutic agents to improve its prognosis. Demethylzeylasteral (ZST93) is a novel triterpenoid monomer extracted from the xylem of Tripterygium roots. Our study aimed to assess the effects of ZST93 on cell proliferation and its role in the chemosensitivity to gemcitabine in human pancreatic cancer cells. The effects of ZST93 on cancer cell proliferation, cell cycle distribution, apoptosis and autophagy were evaluated in various human pancreatic cancer cell lines, and the antitumor effects of ZST93 alone and in combination with gemcitabine were identified in a xenograft mouse model. The results showed that ZST93 could inhibit the proliferation of pancreatic cancer cells and arrest cell cycle at G0/G1 phase by regulating the expression of Cyclin D1 and Cyclin A2. Moreover, ZST93 killed pancreatic cancer cells through two different mechanisms: inducing autophagic cell death at low concentrations and apoptotic cell death at high concentrations. Furthermore, ZST93 could enhance the chemosensitivity of pancreatic cancer cells to gemcitabine both in vitro and in vivo through modulation of the cross talk between autophagy and apoptosis. ZST93 is a potential therapeutic agent for developing novel therapeutic strategies in human pancreatic cancer.
not involved in this process. 8, 9 Researchers have found that apoptosis and autophagy are often induced by the same stimuli, such as chemotherapeutic agents, and there are complex cross-talk mechanisms between these two processes. 9, 10 Tripterygium wilfordii Hook F (TWHF), commonly known as "lei gong teng" or "thunder god vine," has been widely used to treat autoimmune and inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE) and psoriasis. [11] [12] [13] [14] The major therapeutic effects of TWHF have been attributed to its diterpenoid and triterpenoid extracts, such as triptolide and celastrol. [13] [14] [15] Studies have shown that both triptolide and celastrol exert certain anticancer effects through cell cycle arrest or by inducing apoptotic/ autophagic cell death. 9, 16, 17 Demethylzeylasteral (ZST93) is a novel triterpenoid monomer extracted by the Department of Pharmacy, Zhongshan Hospital of Fudan University, from the xylem of the TWHF root. 18 Previous study has shown that ZST93 is abundant (1.973 mg/g) in TWHF. 19 And the cytotoxicity test using mice lymphocyte revealed that ZST93 is significantly less toxic than triptolide (C. Yang et al., unpublished results). Moreover, the in vivo toxicity test using male mice demonstrated that the median lethal dose (LD50) of ZST93 through oral gavage ranged from 283.37 to 288.37 mg/kg, while the LD50 of triptolide ranged only from 0.663 to 0.936 mg/kg. 20 The immunosuppressive effects of ZST93 have been elucidated previously, but little is known regarding its antitumor effects. [20] [21] [22] No study has been conducted to investigate its effects on PC.
In our study, we investigated (1) the antitumor effects of ZST93 against PC and their possible mechanisms and (2) the effect of ZST93 on the PC cells' chemosensitivity to gemcitabine. Our results indicated for the first time that ZST93 inhibited the proliferation of PC cells by arresting the cell cycle and inducing cell death through two different mechanisms: inducing autophagic cell death at low concentrations and inducing apoptotic cell death at high concentrations. Furthermore, ZST93 could enhance PC cells' chemosensitivity to gemcitabine both in vitro and in vivo by modulating the cross talk between autophagy and apoptosis.
Results

ZST93 inhibits human PC cell proliferation in vitro
The chemical structural formula of ZST93 is shown in Figure 1a . To investigate the effects of ZST93 on the in vitro proliferation, six PC cell lines were treated with increasing concentrations of ZST93 for 72 hr, and CCK-8 assay was performed to determine the inhibition rates. The results indicated that all the six cell lines showed significant dosedependent inhibition of proliferation after treatment with ZST93 (Fig. 1b) . Two cell lines, MIA PaCa-2 (relatively more sensitive to ZST93) and PANC-1 (relatively less sensitive to ZST93), were selected for further experiments. Both cell lines were treated with different concentrations of ZST93 for 24, 48, or 72 hr, and the CCK-8 and cell counting assays were performed to determine the inhibition rates. The results showed that ZST93 inhibited the proliferation of both cell lines in a time-and dose-dependent manner (Figs. 1c, 1d , 1f, and 1g). The IC50 of ZST93 for both cell lines was determined by growth inhibition curves according to CCK8 assay, and the results are shown in Figures 1e and 1h; this information helped us determine the concentrations of ZST93 to use in the indicated cells in the following experiments.
ZST93 induces G0/G1 arrest in human PC cells in a dosedependent manner by regulating Cyclin D1 and Cyclin A2 expression
To test the effect of ZST93 on the cell cycle of human PC cells, MIA PaCa-2 and PANC-1 cells were treated with different concentrations of ZST93 for 72 hr before flow cytometry. As shown in Figures 2a and 2b , the cell cycles of both cell lines treated with ZST93 were arrested in the G0/G1 phase in a dose-dependent manner. To investigate the possible mechanisms by which ZST93 regulates the cell cycle, real-time RT-PCR was performed to determine the expression of Cyclin D1 and Cyclin A2, which are considered as checkpoint regulators of the G1-S phase. The results showed that ZST93 inhibited both Cyclin D1 and Cyclin A2 mRNA expression in MIA PaCa-2 and PANC-1 cells in a dose-dependent manner (Figs. 2c-2f ). These data indicated that ZST93 could regulate the cell cycle transition in PC cells, at least partly through the modulation of Cyclin D1 and Cyclin A2 mRNA expression.
ZST93 induces apoptotic or autophagic cell death in human PC cells at different concentrations
To elucidate the mechanisms by which ZST93 causes cell death in PC cells, we examined the proportion of apoptosis and the caspase-3 activity in MIA PaCa-2 and PANC-1 cells.
What's new?
Pancreatic cancer is an aggressive disease, marked by early metastasis, resistance to chemoradiotherapy, and low survival rates. Moreover, response rates to existing chemotherapeutic agents are poor, necessitating the development of new therapies. In this study, demethylzeylasteral (ZST93), a compound isolated from the plant Tripterygium wilfordii, was investigated for its effects on human pancreatic cancer cell lines and xenograft tumors in mice. Both in vitro and in vivo, ZST93 inhibited cancer cell proliferation and increased sensitivity to gemcitabine. Enhanced gemcitabine chemosensitivity in human pancreatic cancer cells was associated with excessive ZST93-induced autophagic or apoptotic cell death.
As shown in Figures 3a and 3b , ZST93 could induce a significant increase in cell apoptosis at high concentrations, but not at low concentrations, in both cell lines. Meanwhile, the detection of active caspase-3 showed that ZST93 increased the level of active caspase-3 in a dose-dependent manner in both cell lines (Figs. 3c and 3d) . Moreover, Z-VAD-FMK, a caspase inhibitor that inhibits caspase-3 activity, could inhibit ZST93-induced apoptosis (Figs. 3a and 3b ) and partially restore cell viability (Figs. 3e and 3f) . Taken together, these data suggest that ZST93 is responsible for caspase-3-dependent apoptosis in PC cells only at high concentrations, but not at low concentrations.
Because ZST93 could indeed induce cell death in PC cells at low concentrations, we tested another cell death mechanism, autophagy, in both cell lines. The autophagy level was determined by monitoring the formation of autophagosome-specific protein LC3. LC3 is a biomarker of autophagy and is present in two forms: the cytosolic form, LC3-I, and the membrane-bound form, LC3-II. The cytosolic LC3-I is converted into LC3-II when autophagy process is activated, so the level of autophagy can be measured by the amount of LC3-II or the LC3-II/LC3-I ratio using Western blot analysis, or by the punctate staining pattern of LC3-II using immunofluorescence. Interestingly, our results showed that low concentrations of ZST93 could induce a significantly high level of autophagy in both cell lines, while high concentrations did not show such effects (Figs. 4a and 4b) . Furthermore, the ultrastructure of cells by transmission electron microscopy indicated that the ZST93-induced autophagy has a prodeath effect in PC cells. As shown in Figure 4c , when treated with low concentrations of ZST93, the PC cells' nuclei were distorted, and many autophagosome and autophagic vacuoles were observed in the cytoplasm. Moreover, in some of the treated cells, large autophagic vacuoles occupied the major cellular space, and many mitochondria have been degraded, which represents the introduction of autophagic cell death (Fig. 4d) . These data indicate that low concentrations of ZST93 can induce autophagic cell death in PC cells. Next, we wanted to determine the role of autophagy in ZST93-induced cell death in PC cells.
In order to inhibit the process of autophagy, 3-MA, an inhibitor of autophagy process, as well as siRNA against Data represent the mean 6 SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
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Beclin1 (a protein involved in the initial steps of vesicle nucleation during autophagy), was introduced into cancer cells treated with different concentrations of ZST93. Figure  5a indicates a significant reduction in the levels of Beclin1 after treatment with siRNA. The effect of 3-MA or siRNA against Beclin1 on the ZST93-induced autophagy was evaluated by monitoring the localization of LC3. As shown in Figure 5b , both the introduction of 3-MA and the downregulation of Beclin1 can effectively inhibit the process of autophagy induced by low concentrations of ZST93 in the 2 PC cell lines. Next we monitored the effect of ZST93 on the PC cells viability with the inhibition of autophagy by 3-MA. Unexpectedly, cell viability was not changed when 3-MA was combined with either low or high concentrations of ZST93 in the two cell lines (Fig. 5c ). Since the inhibition of autophagy was unable to protect PC cells from autophagic cell death mediated by low concentrations of ZST93, there must be an alternate mechanism of cell death. Considering the reports indicating that there is cross talk between apoptosis and autophagy, 9 we then examined the effect of 3-MA on ZST93-induced apoptosis in PC cells. The results showed that 3-MA increased the level of apoptosis when combined with both low and high concentrations of ZST93 (Fig. 5d ). These data suggest that ZST93 might participate in a cross talk between autophagy and apoptosis and induce cell death in PC cells.
ZST93 enhances PC cells' chemosensitivity to gemcitabine in vitro via autophagy and apoptosis
The CCK-8 and cell counting assays were performed to determine the effect of ZST93 on PC cells' chemosensitivity to gemcitabine. Our data showed that combination therapy exhibited a more inhibitory effect on both MIA PaCa-2 and PANC-1 cells (Fig. 6a ). When combined with a low concentration of ZST93 (0.1 lg/ml), the IC50 of gemcitabine in MIA PaCa-2 cells at 72 hr was significantly reduced from 4.09 6 0.57 to 2.32 6 0.11 ng/ml, p 5 0.006. And it was reduced to 0.69 6 0.04 ng/ml when combined with 1 lg/ml ZST93, p 5 0.0005 (Fig. 6b) . Similar results were observed in PANC-1 cells: the IC50 of gemcitabine at 72 hr was reduced from 13.51 6 6.02 to 0.76 6 0.23 lg/ml when combined with a low concentration of ZST93 (0.5 lg/ml), p 5 0.0214, and 0.07 6 0.04 lg/ml with a high concentration of ZST93 (5 lg/ ml), p 5 0.018 (Fig. 6b) . These data indicate that ZST93 could enhance PC cells' chemosensitivity to gemcitabine in vitro, either at low concentrations or at high concentrations. The effects of ZST93-induced autophagy and apoptosis on chemosensitivity were evaluated in subsequent experiments. The results indicated that gemcitabine alone induces cell death in both PC cell lines by inducing the caspase-3-dependent apoptosis, but not autophagy (Figs. 6c-6f ). The combination with low concentrations of ZST93 significantly increased the autophagy process in both cell lines, but the gemcitabine-induced apoptosis seemed to be partly rescued by additional low concentrations of ZST93. In contrast, when gemcitabine was combined with high concentrations of ZST93, a further increased level of casepase-3-dependent apoptosis, but not autophagy, was introduced, as shown in Figures 6c-6f . Furthermore, when 3-MA was added to inhibit the autophagy process, the autophagy induced by low concentrations of ZST93 was completely reversed to increased levels of apoptosis. And 3-MA could further enhance the apoptosis process induced by the combination of gemcitabine and high concentrations of ZST93 (Figs. 6e and 6f) . It should be noted that when a high concentration of gemcitabine (1,000 lg/ml) was used to treat PANC-1 cells, the addition of a high concentration of ZST93 (5 lg/ml) could not further increase the apoptosis rate; however, when the autophagy process was inhibited by 3-MA, the apoptosis rate was further increased significantly (Fig. 6f) . These data suggest that ZST93 could enhance PC cells' chemosensitivity to gemcitabine via the regulation of cross talk between autophagy and apoptosis.
The in vivo effect of ZST93 on human PC cells' tumor growth and chemosensitivity to gemcitabine
To investigate the inhibitory effect of ZST93 on human PC cells in vivo, MIA PaCa-2 cells were used to establish a nude mouse xenograft model for in vivo experiments. The nude mice were randomly assigned to one of six groups: the control group, the low-dose ZST93 group, the moderate-dose ZST93 group, the high-dose ZST93 group, the gemcitabine group, and the combined treatment (gemcitabine combined with moderate-dose ZST93) group. All the nude mice were sacrificed on Day 30 after treatment, and the xenograft tumors were removed and weighed. A TUNEL assay was performed to examine the apoptosis level, and the Ki-67 expression level was determined via immunohistochemistry to reflect the cancer cell proliferation. The level of autophagy was measured by the LC3-II/LC3-I ratio using Western blot analysis. The results showed that ZST93 inhibited tumor growth in vivo in a dose-dependent manner (Figs. 7a-7c ) by inducing tumor apoptosis (Fig. 5d ) and inhibiting cancer cell proliferation (Fig. 7e) . However, the level of autophagy was not changed after treatment with any dose of ZST93 (Fig. 7f) , indicating that the doses used in vivo were not comparable with the "low concentrations" used in vitro. Moreover, the combination of gemcitabine and ZST93 exhibited a more potent inhibitory effect on tumor growth than gemcitabine chemotherapy alone (Figs. 7g-7i) by further increasing the apoptosis rate (Fig. 7j) and inhibiting the proliferation of cancer cells (Fig. 7k) .
Discussion
In the present study, we confirm for the first time that ZST93, a triterpenoid monomer extracted from the xylem of the TWHF root, can inhibit human PC cells' proliferation and enhance cellular chemosensitivity to gemcitabine both in vitro and in vivo. ZST93 is responsible for G0/G1 cell cycle arrest in PC cells by repressing the expression of Cyclin D1 and Cyclin A2. In addition, ZST93 induces autophagic cell death at low concentrations or caspase-3-dependent apoptotic cell death at high concentrations. Moreover, ZST93 enhances chemosensitivity to gemcitabine via the modulation of apoptotic and autophagic cell death. The inhibition of autophagy can further strengthen ZST93-induced apoptotic cell death in vitro.
It has been reported previously that triptolide could induce cell cycle arrest in the S phase in human fibrosarcoma and breast cancer cell lines. 23 In colon cancer cells, triptolide was reported to be able to induce G1 cell cycle arrest by inhibiting transcriptional activation of E2F1. 16 However, the study of PC cell lines did not show that triptolide exerted any effect on cell cycle arrest. 9 Our results indicate that ZST93 induces a significant G0/G1 cell cycle arrest in human PC cell lines in a dose-dependent manner by inhibiting the mRNA expression of Cyclin D1 and Cyclin A2 (Fig. 2) . These data suggest that ZST93 and triptolide might exert inhibitory effects on human PC cell proliferation through different mechanisms. Studies have shown that both triptolide and celastrol can induce caspase-dependent apoptotic cell death in human PC cells. 9, 17 Mujumdar et al. found that triptolide induced cell death via two different pathways in different PC cell lines. 9 In the MIA PaCa-2, Capan-1 and BxPC-3 cell lines, triptolide induced caspase-dependent apoptotic death, while in the metastatic cell lines S2-013, S2-VP10 and Hs766T, it induced caspase-independent autophagic death. Interestingly, these results showed that in the absence of autophagy, triptolide could induce apoptotic cell death in S2-013 and S2-VP10 cells, while this conversion was not observed in MIA PaCa-2 cells, indicating that triptolide exerted antitumor effects through different mechanisms in different PC cell lines. 9 Our study shows that ZST93 induces either apoptotic or autophagic cell death at different concentrations in human PC cells. ZST93 induces a significant increase in caspase-3-dependent apoptosis at high concentrations in both MIA PaCa-2 and PANC-1 cells but not at low concentrations. Low concentrations of ZST93 can induce autophagy, with a slightly increased level of active caspase-3, but not increase the apoptosis rate in both PC cell lines (Figs. 3 and 4) . We consider the ZST93-induced autophagy as a prodeath mechanism, but not a prosurvival process, because of the followings: (1) the induction of autophagy was associated with significant cell death, but not a protection of the cell viability and (2) the results of transmission electron microscopy also indicated autophagic cell death. All these data suggest that when treated with low concentrations of ZST93, PC cells were killed via autophagic cell death, but not apoptosis. The mechanism of caspase-independent autophagic cell death in PC cells remains unclear. Wang et al. reported that gemcitabine could induce autophagic cell death through promoting the degradation of PARP-1 in PC cells. 24 Mujumdar et al. demonstrated that the triptolide-induced autophagy was associated with the inactivation of the Akt/mTOR/p70S6K pathway and the upregulation of the ERK1/2 pathway. 9 The exact mechanisms of ZST93-induced autophagy and its relationship with PC cells death merit further investigation.
Partially concurring with the results of Mujumdar et al., 9 our results confirm that cross talk occurs between the autophagic and apoptotic pathway in human PC cells when treated with ZST93. When the autophagy process is inhibited, cell viability is not rescued because of the conversion from autophagic death to apoptotic death. In contrast, the inhibition of caspase-dependent apoptosis with Z-VAD-FMK partially rescued cell viability when either low or high concentrations of ZST93 were added. Incubation with a low concentration of ZST93 did not induce a significant increase in the apoptosis rate, but the levels of active caspase-3 were already upregulated. In addition, Z-VAD-FMK could decrease the apoptosis rate and partially rescue cell viability, although at this concentration, ZST93 induces cell death mainly via autophagy but not apoptosis. These data suggest that the PC cells treated with ZST93 harbor an intact apoptotic machinery, but they preferentially activated the autophagic death pathway in response to low concentrations of ZST93. Triptolide has been reported to increase chemotherapyinduced cell growth arrest and the apoptosis rate, hence enhancing the antitumor effect of gemcitabine in human PC cells. 25 In our study, we proved for the first time that ZST93 enhanced human PC cells' chemosensitivity to gemcitabine both in vitro and in vivo. When combined with different concentrations of ZST93, the IC50 of gemcitabine in PC cell lines was significantly decreased. In addition, the combination treatment inhibited cancer cell growth both in vitro and in vivo compared to gemcitabine treatment alone. The mechanism of this synergistic antitumor activity is the induction of either autophagic or apoptotic cell death when combined with different concentrations of ZST93. Gemcitabine increases the caspase-3 activity and apoptosis rate in PC cell lines. When low concentrations of ZST93 are added, the caspase-3 activity and apoptosis rate are inhibited and autophagic cell death is upregulated, resulting in an increased anticancer effect. In contrast, when high concentrations of ZST93 are added, the gemcitabine-induced apoptosis rate is further increased with an upregulated caspase-3 activity, while the autophagy process seems to be inhibited to nearly normal levels. Moreover, the same cross talk between autophagy and apoptosis occurs in combination therapy. When gemcitabine was combined with either low or high concentrations of ZST93, inhibition of autophagy with 3-MA could further increase the apoptotic cell death, but not rescue the cancer cell viability. We noted that in the PANC-1 cell line, when a high dose of gemcitabine (1,000 lg/ml) was combined with a high concentration of ZST93 (5 lg/ml), the apoptosis rate was no longer upregulated compared to gemcitabine treatment alone, until the autophagy process was inhibited by 3-MA. Hence, triple combination therapy further enhances the synergistic antitumor activity in PC cells, and it might provide a more promising combinative therapeutic strategy for this devastating disease.
Our study provides some preliminary evidence that ZST93, a triterpenoid monomer extracted from the TWHF root, could be a novel and promising therapeutic agent for the treatment of human PC. However, the molecular mechanisms by which ZST93 induces cancer cell apoptosis and autophagy remain not clear, and the relationship between ZST93-induced apoptotic and autophagic cell death also merits further investigation. Previous studies have shown that autophagy and apoptosis are often induced by the same stimuli and that complex cross talk occurs between the two pathways. 10 The switch between autophagy and apoptosis is reportedly determined by a few key molecular players that are common to both processes, for example, ER localization of BCL2 or BCL-XL, nuclear or cytoplasmic accumulation of p53 and mitochondrial translocation of the shorter isoform of p14ARF. [26] [27] [28] Further evaluating the effect of ZST93 on these regulators of autophagy and apoptosis will help explain why the PC cells respond differently to different concentrations of ZST93. Our further study will focus on these molecular mechanisms.
In conclusion, our study shows that ZST93 inhibits PC cell proliferation via arresting cell cycle and induces cancer cell death by modulating the cross talk of autophagic and apoptotic pathways. ZST93 enhances PC cells' chemosensitivity to gemcitabine, by inducing either excessive autophagic or apoptotic cell death. Furthermore, the inhibition of autophagy further increases the apoptosis rate induced by the combination of gemcitabine with either a high or a low concentration of ZST93. All these data indicate that ZST93 is an attractive novel chemotherapeutic agent against human PC, and the combinatory therapeutic strategy based on ZST93 and gemcitabine might offer improvements in PC treatment.
Material and Methods
Ethics statement
All the animal studies performed here were reviewed and approved by the Ethics Committee for Animal Studies at Peking University, China.
Reagents and antibodies
ZST93 (yellow powder, molecular formula: C 29 H 36 O 6 , molecular weight: 480) was provided by Prof. Yang Chunxin of the Department of Pharmacy, Zhongshan Hospital of Fudan University. ZST93 is a triterpenoid extracted from Tripterygium, and its chemical formula is shown in Figure 1a . DMEM medium, RPMI-1640 medium and fetal bovine serum (FBS) were purchased from Gibco, Inc. (Grand Island, NY); 3-MA and Z-VAD-FMK were purchased from Selleckchem (Houston, TX); the anti-b-actin antibody was purchased from MBL Technologies (Woburn, MA); the anticleaved caspase-3 and anti-LC3 antibodies were purchased from Cell Signaling Technology (Danvers, MA); the anti-caspase-3 and anti-Ki-67 antibodies were purchased from Abcam (Cambridge, MA); injectable gemcitabine hydrochloride was purchased from Eli Lilly (Indianapolis, IN); 6-week-old BALB/c nude mice (16-20 g ) were purchased from the Department of Laboratory Animal Science, Peking University Health Science Center.
Cell culture
The PC cell lines T3M4, Colo-357, Capan-1, ASPC-1, MIA PaCa-2 and PANC-1 were obtained from the American Type Culture Collection where they were characterized by mycoplasma detection, DNA-Fingerprinting, isozyme detection and cell vitality detection. These cell lines were immediately expanded and frozen so that they could be restarted every 3-4 months from a frozen vial of the same batch of cells. All the cell lines were cultured in DMEM or RPMI-1640 media supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (100 mg/ml). The cells were maintained at 378C in a humidified atmosphere of 5% CO 2 .
CCK-8 assay
The cells were plated at a density of 3,000 cells/well in 96-well plates. After different treatments, WST-8 reagent from Cell Counting Kit-8 (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) was added (10 ml/well), and the plates were then incubated for 2 hr. The OD values for all experimental groups were obtained at an optical absorbance (A) of 450 nm and were normalized to the values of the control group.
Inhibition rate (%) 5 100% 2 [A(experiment) 2 A(blank)]/ [A(control) 2 A(blank)] 3 100%. The IC50 of each cell line was determined using SPSS software according to the results of inhibition rates by CCK-8 assay.
Cell counting assay
The cells were plated at the same density (30,000 cells/well) in six-well plates. After different treatments, cells were harvested in 1 ml DMEM. The samples were prepared by adding 10 ll of cell suspension to 10 ll of 0.4% trypan blue stain. 
Cell cycle analysis
Cells were seeded into six-well plates and grown to 80% confluence in the logarithmic growth phase. The serum was deprived for 24 hr to synchronize cells. The cells were washed three times with PBS and cultured in medium supplemented with 10% fetal bovine. After different treatments, the cells were harvested, washed with PBS and fixed with 70% precooled ethanol at 48C for at least 4 hr. Then, the cells were incubated in PBS solution containing 50 mg/ml propidium iodide (PI) and 100 mg/ml RNase for 30 min at room temperature. Finally, the cell cycle was analyzed using BD FACSCalibur flow cytometry (BD Biosciences, San Jose, CA) within 1 hr.
Real-time RT-PCR
Total RNA was extracted from the cells using TRIZOL Reagent (Invitrogen, Carlsbad, CA). First-strand cDNA was synthesized using the ReverTra AceV R qPCR RT kit according to the manufacturer's protocol (TOYOBO, Tokyo, Japan). Real-time RT-PCR was performed with SYBR Green PCR Master Mix (TOYOBO). GAPDH was used as an internal control. The primers used were as follows: GAPDH 5 0 -ACGGATTTGGTCGTATTGGG-3 0 and 5 0 -TGATTTTGGA GGGATCTCGC-3 0 ; Cyclin D1 5 0 -ACGAAGGTCTGCGCG TGTT-3 0 and 5 0 -CCGCTGGCCATGAACTACCT-3 0 ; Cyclin A2 5 0 -CAGTGTGAAGATGCCCTGGCTT-3 0 and 5 0 -CAAG GATGGCCCGCATACTGTTA-3 0 . The relative quantification of gene expression was calculated on triplicate reactions using the ᭝᭝ Ct method. Data were analyzed using ABI 7500 software v2.0.6 (Applied Biosystems, Foster City, CA, USA).
Western blot analysis
Total cellular protein was extracted with RIPA buffer, and the total protein concentration was measured using a BCA Protein Assay Kit (Thermo Scientific, USA). Then, the proteins (25 mg/lane) were separated on 10% SDS-PAGE and transferred to PVDF membranes. The membranes were blocked with 5% nonfat dry milk in Tris-buffered saline with 0.1% Tween 20 and were incubated with the primary antibodies, followed by incubation with HRP-conjugated secondary antibodies. The peroxidase activity was detected using Immobilon Western Chemiluminescent HRP Substrate (Millipore, USA) after exposure to X-ray film. b-Actin was used as the loading control.
Cell apoptosis analysis via flow cytometry
Cells in an exponential growth phase were harvested and seeded onto six-well plates. Once the cells adhered to the plate, different concentrations of gemcitabine and/or ZST93 were added to cells in the experimental group; 0.1% DMSOcontaining medium was used as a control. After the cells were cultured for 72 hr, an Annexin V-FITC/PI Apoptosis Assay Kit (BD Biosciences) was used to measure the percentage of apoptotic cells. The apoptosis process was analyzed using BD FACS Calibur flow cytometry (BD Biosciences) within 1 hr. Apoptotic cells were defined as Annexin V 1 and PI 6 cells. And the apoptotic rate was calculated as the amount of the percentages of both upper right quadrant and lower right quadrant.
Immunofluorescence
The cells were grown, treated, fixed, then stained using antiLC3b. After incubation with the secondary antibody, the slides were mounted. The images were obtained using a fluorescence microscope.
Electron microscopic observation
Electron microscopic observation was performed to morphologically demonstrate the autophagosomes. After different treatments, the cells were collected and washed twice with PBS. Then the cells were fixed with ice-cold glutaraldehyde (2.5% in 0.1 mmol/l cacodylate buffer, pH 7.4) for 30 min. The cells were fixed in OsO 4 , dehydrated through an acetone series, and then embedded in epon. Thin sections of the cells (0.1 mm) were stained with uranyl acetate/lead citrate (Fluka), and then viewed under electron microscope. 
Xenograft model
Six-week-old male BALB/c nude mice weighing 16-20 g were randomly assigned using a random number sheet to one of six groups, each of which contained six mice. During the experiment, 1 3 10 7 MIA PaCa-2 cells were suspended in 200 ll of PBS and injected into the axillary fossa of the nude mice. Tumor growth was monitored regularly. From Day 15 after inoculation, the low-dose, moderate-dose and high-dose ZST93 groups received a daily oral gavage with the appropriate dose of ZST93 (80 mg/kg for the low-dose group, 160 mg/kg for the moderate-dose group and 200 mg/kg for the high-dose group, once a day) dissolved in the same volume of 5% ethanol and an intraperitoneal injection of PBS every 3 days. The control group received a daily oral gavage with an equal volume of 5% ethanol solution and an intraperitoneal injection of PBS every 3 days. The gemcitabine group received an intraperitoneal injection of gemcitabine (50 mg/kg) every 3 days and daily oral gavage with 5% ethanol solution. The combined treatment group received an intraperitoneal injection of gemcitabine (50 mg/kg) every 3 days and daily oral gavage with a moderate dose of ZST93 (160 mg/kg, once a day). The length (a) and width (b) of the xenograft tumors were measured every 5 days, and the xenograft volume was calculated according to V 5 (a 3 b 2 )/2. The nude mice were sacrificed on Day 45 (Day 30 after treatment), and the xenograft tumors were removed and weighed. A portion of the tumor tissue was collected, fixed in 4% paraform and embedded in paraffin for immunohistochemical staining.
Immunohistochemical staining
The xenograft tissues collected from the nude mice were fixed in 4% paraformaldehyde, embedded in paraffin, and then deparaffinized and rehydrated. After antigen retrieval, the sections were immersed in 0.3% hydrogen peroxide for 15 min and then incubated with the Ki-67 antibody overnight at 48C. Next, the sections were incubated with an HRP secondary antibody and were observed under the microscope. Five fields were randomly selected to calculate the positivity rate of Ki-67 staining.
TUNEL assay
Apoptosis of the xenograft tissues was detected using a TUNEL in situ apoptosis detection kit (KeyGEN BioTECH, Nanjing, China) according to the package insert. After the tissue was observed under the microscope, five fields were randomly selected to calculate the rate of apoptosis.
Statistical analysis SPSS 20.0 software (SPSS, Chicago, IL) was used for the statistical analysis. The data were expressed as the mean 6 standard deviation, and an independent sample t test was performed to compare the mean values among the groups unless otherwise stated. The in vivo tumor growth curves between groups were statistical analyzed by two-way ANOVA. p < 0.05 was considered statistically significant.
